Study of 305 newly Dx axSpA pts (age 38 yrs; 55% male, Dx delay 6yrs, 75% B27+). Clinical Dx, without Xray/imaging in 12%, 5% developed sacroiliitis during 8 yr F/U. r-axSpA mostly male w/ ^CRP https://t.co/zGjb3uSkjP https://t.co/3bdGAvKXAm

• Insights into axial spondyloarthritis features and the development of imaging e…

Medical Economics reports only 18% MDs practiced in MD-owned settings, a new low. By Jan '26 hospitals or corporate employment rose to 550,494 & independent MDs fell to 120,900 https://t.co/l0tt3yO9kt https://t.co/pkgmHFPjE1

• Physician independence vanishes as corporate medicine swallows up U.S. health c…

Depression screening (PHQ-8) equally accurate in pts w/ & w/o chronic pain. Depression screening is not biased by overlapping symptoms in depression and chronic pain. https://t.co/UWf97NDPAK https://t.co/7dvt35RT9E

• https://buff.ly/DoE4qHf

Infectious Rheumatology (5.15.2026) Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow. https://t.co/MzqDykG78w https://t.co/z7BsADXo4x

• Infectious Rheumatology (5.15.2026) | RheumNow

Update on Multicentric Reticulohistiocytosis Have you ever seen multicentric reticulohistiocytosis (MRH)? Don't worry, it's a rare non-Langerhans cell histiocytosis condition characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and it has only been https://t.co/koXOwktDgA

FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/qqPsjhUClP https://t.co/lCZNoTh9fv

• ​​FASENRA​ approved in ​US​ for ​hypereosinophilic syndrome​

ANCA-Assoc. Vasculitis has great Rx optionis, BUT still no reliable biomaker to predict relapse or renal outcomes, this includes IL-6. But there is hope for CD163 in the future. https://t.co/lFyfTPj5vG https://t.co/wLfOPz76JC

• Anti-neutrophil cytoplasmic antibody-associated vasculitis: biological insights…

10yr retrosp. study of 110 Still’s dz pts. MAS occurred in 37% (1/2 @onset; assoc w/ serositis) and ILD observed in 82% (also assoc w/ MAS, polycyclic course) https://t.co/SNa0KiWfgY https://t.co/xbpCuHdJka

• Clinical course, complications and treatment outcomes in Still’s disease: a 10-…

Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/y0mw7tRWbs

Fatigue in SLE An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients. https://t.co/JEAnhMFJD8 https://t.co/sROKzsyISl

• Fatigue in SLE | RheumNow

"Everything will be alright in the end; and if its not alright, then its not yet the end" – Suni Kapoor Best exotic Marigold Hotel https://t.co/Yua7t4yoZe

Registry of 587 #SLE pts. 30% were RNP+ --> more dz activity than RNP- (SLEDAI-2 8.0 vs 4.0) and more Rx use (daily GC 6.8 vs 3 mg). RNP+  more renal, skin & serologic activity & less likely to LLDAS (20% vs 32%) or REM (12% vs 23%). RNP + 18-fold more likely to be Sm+ https://t.co/9i3BBGA0uu